EIT-URBAN-MOBILITY
Tomorrow.Mobility World Congress (TMWC) is a new global event, co-organised by Fira de Barcelona and EIT Urban Mobility, focused on promoting the design and adoption of new sustainable urban mobility models. TMWC is being launched to create a global benchmark in the field of mobility and to go beyond a one-off event, as it will include an online knowledge platform that will be active throughout the year and an innovation hub set to bring the main players in the industry together.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211116005046/en/
EIT Urban Mobility is the largest European initiative for the transformation of urban mobility, created by the European Institute of Innovation and Technology (EIT), a body of the European Union. This European initiative benefits of the strategic partnership with Fira de Barcelona by increasing the impact of its European partnership and jointly reaching to a wider audience globally in the mobility scene. Tomorrow.Mobility represents EIT Urban Mobility’s flagship event 2021, showcasing its most promising innovation projects, results, demonstrations, and supported start-ups.
TMWC will bring insights from the global mobility ecosystem gathered under one roof. Being aware of the strong ties that mobility has with other sectors, the event is co-located with Smart City Expo World Congress (SCEWC). More than 350 speakers will be joining alongside hundreds of exhibitors and thousands of attendees. Twelve inspiring congress sessions featuring high-level speakers from both the public and private sector will take place under the umbrella of Tomorrow.Mobility. Speakers include Maria Tsavachidis, CEO of EIT Urban Mobility & President of the Board of Tomorrow.Mobility; Matthew Baldwin, Deputy Director-General for DG MOVE, European Commission; Mark Major, Senior Advisor to the Partnership on Sustainable, Low Carbon Transport (SLoCaT); Carlos Moreno, Scientific director of the Chair Entrepreneurship Territory Innovation, University Panthéon Sorbonne – IAE Paris; and Anna Lisa Boni, Secretary General at Eurocities.
Dr. Maria Tsavachidis, CEO of EIT Urban Mobility & President of the Advisory Board of TMWC stated that “our collaboration with Fira de Barcelona will help expand the network of innovation for urban mobility in Europe and beyond. Our goal is to foster innovation and transformation towards sustainable mobility, to decarbonise mobility, improve people’s quality of life, and make Europe’s economy more competitive. Bringing together the world´s leaders and frontrunners in sustainable mobility under the umbrella of Tomorrow.Mobility is an important steppingstone towards this goal. It will inspire and create new opportunities for our partners, cities, startups, and their innovations ”.
Numerous start-ups supported by EIT Urban Mobility will be showcasing their high-tech solutions at their booths and demo areas, such as: Bia Power (Autonomous Vehicles/Spain), BlockCity (Mobility Services/Hungary), Dashfactory Gmbh (Sensors & Training Data/Germany), Delivers.ai (Last Mile Delivery/Turkey), Vianova (Sensors Data/France), and SmartMonkey (Green Logistics/Spain).
Several EIT Urban Mobility supported innovation projects will be featured at the Central Agora during two different sessions. One session focusing on managing shared public space, and another on how to put Mobility as a Service (MaaS) solutions into practice. Among the EIT Urban Mobility supported projects presented are, FURNISH , which promotes the redesign of public spaces to prevent the spread of COVID-19. Another notable project is HALLO, which creates shared urban consolidation and distribution centres through a series of pilots in Barcelona and Stockholm.
Tomorrow.Mobility, held with the Smart City Expo World Congress (SCEWC), a leading tradeshow & congress on smart cities, has the initial support of over a hundred global companies and trusted institutions amongst which feature the World Bank, the World Economic Forum, the United Nations, Microsoft, Mastercard, ADP (Airports of Paris), the International Association of Ports and Harbours, the Port of Barcelona, Moventia, the RACC and Social Car. The event seeks to tackle the future challenges facing mobility, an industry that will be one of the main drivers of future growth, with a market volume of 60,000 million euros in 2027.
The new event, which will include a congress and exhibition area, will hold a first pilot edition in November and again in 2022. It will address current mobility challenge areas such as micromobility (electric scooters, bicycles), active mobility and the public realm, public transport, mobility providers (car sharing, air taxis), the car industry (electric, connected, and autonomous cars), last mile logistics (e-commerce deliveries, delivery drones), smart infrastructures (fleet management, geolocation, and payment systems), the energy transition towards carbon neutrality and digitisation.
The objective of Tomorrow.Mobility is to go beyond being just an event. The launch of the new show will be accompanied by the creation of a digital content platform with a global reach operating 365 days a year, turning it into the go-to global stage for urban, sustainable, and smart mobility. This platform will allow access to both live events and à la carte contents divided into themes with the aim of facilitating knowledge transfer, training & network.
Practical information
- Dates: 16, 17 & 18 November 2021
- Opening hours: Tue & Wed: 9.00-19.00 CET | Thu: 9.00-17.00 CET
-
Location:
Fira de Barcelona Gran Via – Halls 1 & 2 -
Av. Joan Carles I, 64 - 08908 L’Hospitalet de Llobregat, Barcelona, Spain - EIT Urban Mobility Booth @ Tomorrow.Mobility: Street D, Stand 174
- Event website: www.tomorrowmobility.com
BACKGROUND
About EIT Urban Mobility
EIT Urban Mobility, an initiative of the European Institute of Innovation and Technology (EIT)
, a body of the European Union, aims to accelerate solutions and the transition towards a user-centric, integrated and truly multimodal transport system. As the leading European innovation community for urban mobility, EIT Urban Mobility works to avoid fragmentation by facilitating collaboration between cities, industry, academia, research and innovation to solve the most pressing mobility challenges of cities. Using cities as living labs, its industry, research and university partners will demonstrate how new technologies can work to solve real problems in real cities by transporting people, goods and waste in smarter ways.
For more information visit www.eiturbanmobility.eu .
Follow EIT Urban Mobility on: Linkedin Twitter Facebook Youtube Instagram
View source version on businesswire.com: https://www.businesswire.com/news/home/20211116005046/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom